{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:33:38Z","timestamp":1794620018259,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872438"],"award-info":[{"award-number":["81872438"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Program of Research and Development of Key Common Technologies and Engineering of Major Scientific and Technological Achievements in Hefei","award":["2021YL007"],"award-info":[{"award-number":["2021YL007"]}]},{"name":"Collaborative Innovation Program of Hefei Science Center, Chinese Academy of Sciences","award":["2022HSC-CIP015"],"award-info":[{"award-number":["2022HSC-CIP015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hepatocellular carcinoma (HCC) is characterized by the synchronization of tumor cell proliferation and an immunosuppressive microenvironment. Decoupling these interconnected processes represents a major therapeutic challenge. Although Prostaglandin E Synthase 3 (PTGES3) functions canonically as a cytoplasmic Heat Shock Protein 90 (HSP90) co-chaperone, its non-canonical nuclear role in orchestrating tumor-immune crosstalk remains undefined. Here, we identify PTGES3 as a dual-function regulator coupling tumor intrinsic growth with extrinsic immune remodeling. We report that PTGES3 is upregulated in HCC and serves as an independent prognostic factor for poor survival. Using an immunocompetent, diethylnitrosamine (DEN)-induced HCC mouse model, we demonstrate that hepatocyte-specific\n                    <jats:italic>Ptges3<\/jats:italic>\n                    silencing significantly suppresses tumorigenesis. Single-cell RNA sequencing (scRNA-seq) and histological analysis reveal that PTGES3 deficiency remodels the immune landscape, specifically by impairing tumor-associated macrophage (TAM) infiltration and M2 polarization. Mechanistically, we identified a specific G-rich motif on the\n                    <jats:italic>Specificity Protein 1<\/jats:italic>\n                    (\n                    <jats:italic>SP1<\/jats:italic>\n                    ) promoter bound by PTGES3 (confirmed via electrophoretic mobility shift assay [EMSA] and Cleavage Under Targets and Tagmentation [CUT&amp;Tag]), which drives SP1-mediated Transforming Growth Factor-\u03b2 (TGF-\u03b2) secretion. This axis appears to exert dual oncogenic effects: triggering paracrine M2 macrophage polarization to foster immunosuppression, whilst simultaneously fueling an autocrine TGF-\u03b2\/TGFBR\/PI3K\/AKT\/mTOR signaling loop to sustain tumor proliferation. Our findings define a non-canonical nuclear function for PTGES3, identifying it as a critical molecular switch that couples tumor aggressiveness with microenvironmental remodeling, thus presenting a promising therapeutic target for HCC.\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00431-6","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:47:20Z","timestamp":1774432040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nuclear prostaglandin E synthase 3 promotes hepatocellular carcinoma growth with immunosuppressive macrophage polarization via the SP1\/TGF-\u03b2 axis"],"prefix":"10.1186","volume":"7","author":[{"given":"Nianfei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanghu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-5029","authenticated-orcid":false,"given":"Bo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"5","key":"431_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","volume":"82","author":"EY Tan","year":"2025","unstructured":"Tan EY, Danpanichkul P, Yong JN, Yu Z, Tan DJH, Lim WH, et al. Liver cancer in 2021: Global Burden of Disease study. J Hepatol. 2025;82(5):851\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.031.","journal-title":"J Hepatol"},{"issue":"1","key":"431_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"431_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17998\/jlc.2024.03.13","volume":"24","author":"DY Kim","year":"2024","unstructured":"Kim DY. Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. J Liver Cancer. 2024;24(1):62\u201370. https:\/\/doi.org\/10.17998\/jlc.2024.03.13.","journal-title":"J Liver Cancer"},{"issue":"6","key":"431_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3322\/caac.70018","volume":"75","author":"D Moris","year":"2025","unstructured":"Moris D, Martinino A, Schiltz S, Allen PJ, Barbas A, Sudan D, et al. Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians. CA Cancer J Clin. 2025;75(6):498\u2013527. https:\/\/doi.org\/10.3322\/caac.70018.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"431_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(4):203\u201322. https:\/\/doi.org\/10.1038\/s41575-022-00704-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"431_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217472","volume":"613","author":"X Jiang","year":"2025","unstructured":"Jiang X, Ge X, Huang Y, Xie F, Chen C, Wang Z, et al. Drug resistance in TKI therapy for hepatocellular carcinoma: mechanisms and strategies. Cancer Lett. 2025;613:217472. https:\/\/doi.org\/10.1016\/j.canlet.2025.217472.","journal-title":"Cancer Lett"},{"issue":"5","key":"431_CR7","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","volume":"77","author":"R Donne","year":"2023","unstructured":"Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77(5):1773\u201396. https:\/\/doi.org\/10.1002\/hep.32740.","journal-title":"Hepatology"},{"issue":"1","key":"431_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025;10(1):35. https:\/\/doi.org\/10.1038\/s41392-024-02075-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"431_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/cac2.12345","volume":"42","author":"K Cheng","year":"2022","unstructured":"Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun. 2022;42(11):1112\u201340. https:\/\/doi.org\/10.1002\/cac2.12345.","journal-title":"Cancer Commun"},{"issue":"5","key":"431_CR10","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jhep.2023.06.022","volume":"79","author":"Y Lu","year":"2023","unstructured":"Lu Y, Sun Q, Guan Q, Zhang Z, He Q, He J, et al. The XOR-IDH3\u03b1 axis controls macrophage polarization in hepatocellular carcinoma. J Hepatol. 2023;79(5):1172\u201384. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.022.","journal-title":"J Hepatol"},{"issue":"11","key":"431_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cac2.12607","volume":"44","author":"J Cai","year":"2024","unstructured":"Cai J, Song L, Zhang F, Wu S, Zhu G, Zhang P, et al. Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer Commun (Lond). 2024;44(11):1231\u201360. https:\/\/doi.org\/10.1002\/cac2.12607.","journal-title":"Cancer Commun (Lond)"},{"issue":"7893","key":"431_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-021-04236-1","volume":"601","author":"CM Noddings","year":"2022","unstructured":"Noddings CM, Wang RY, Johnson JL, Agard DA. Structure of Hsp90-p23-GR reveals the Hsp90 client-remodelling mechanism. Nature. 2022;601(7893):465\u20139. https:\/\/doi.org\/10.1038\/s41586-021-04236-1.","journal-title":"Nature"},{"issue":"1","key":"431_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21063-0","volume":"12","author":"MM Biebl","year":"2021","unstructured":"Biebl MM, Lopez A, Rehn A, Freiburger L, Lawatscheck J, Blank B, et al. Structural elements in the flexible tail of the co-chaperone p23 coordinate client binding and progression of the Hsp90 chaperone cycle. Nat Commun. 2021;12(1):828. https:\/\/doi.org\/10.1038\/s41467-021-21063-0.","journal-title":"Nat Commun"},{"issue":"26","key":"431_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade0387","volume":"9","author":"Z Yu","year":"2023","unstructured":"Yu Z, Peng Y, Gao J, Zhou M, Shi L, Zhao F, et al. The p23 co-chaperone is a succinate-activated COX-2 transcription factor in lung adenocarcinoma tumorigenesis. Sci Adv. 2023;9(26):eade0387. https:\/\/doi.org\/10.1126\/sciadv.ade0387.","journal-title":"Sci Adv"},{"issue":"2","key":"431_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.molcel.2011.05.029","volume":"43","author":"FJ Echtenkamp","year":"2011","unstructured":"Echtenkamp FJ, Zelin E, Oxelmark E, Woo JI, Andrews BJ, Garabedian M, et al. Global functional map of the p23 molecular chaperone reveals an extensive cellular network. Mol Cell. 2011;43(2):229\u201341. https:\/\/doi.org\/10.1016\/j.molcel.2011.05.029.","journal-title":"Mol Cell"},{"key":"431_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1158490","volume":"13","author":"H Wang","year":"2023","unstructured":"Wang H, Sun P, Yao R, Zhang W, Zhou X, Yao J, et al. Comprehensive pan-cancer analysis of PTGES3 and its prognostic role in hepatocellular carcinoma. Front Oncol. 2023;13:1158490. https:\/\/doi.org\/10.3389\/fonc.2023.1158490.","journal-title":"Front Oncol"},{"issue":"1","key":"431_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-024-00580-0","volume":"19","author":"S Liu","year":"2024","unstructured":"Liu S, Yuan F, Dong H, Zhang J, Mao X, Liu Y, et al. PTGES3 proteolysis using the liposomal peptide-PROTAC approach. Biol Direct. 2024;19(1):144. https:\/\/doi.org\/10.1186\/s13062-024-00580-0.","journal-title":"Biol Direct"},{"issue":"1","key":"431_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32283-3","volume":"13","author":"Y Lu","year":"2022","unstructured":"Lu Y, Yang A, Quan C, Pan Y, Zhang H, Li Y, et al. A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma. Nat Commun. 2022;13(1):4594. https:\/\/doi.org\/10.1038\/s41467-022-32283-3.","journal-title":"Nat Commun"},{"issue":"1","key":"431_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-85506-0","volume":"15","author":"H Dai","year":"2025","unstructured":"Dai H, Tao X, Shu Y, Liu F, Cheng X, Li X, et al. Integrating single-cell RNA-Seq and bulk RNA-Seq data to explore the key role of fatty acid metabolism in hepatocellular carcinoma. Sci Rep. 2025;15(1):2077. https:\/\/doi.org\/10.1038\/s41598-025-85506-0.","journal-title":"Sci Rep"},{"issue":"D1","key":"431_CR20","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkx1013","volume":"46","author":"H Han","year":"2018","unstructured":"Han H, Cho JW, Lee S, Yun A, Kim H, Bae D, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46(D1):D380\u20136. https:\/\/doi.org\/10.1093\/nar\/gkx1013.","journal-title":"Nucleic Acids Res"},{"key":"431_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jss.2021.08.033","volume":"271","author":"A Adekeye","year":"2022","unstructured":"Adekeye A, Agarwal D, Nayak A, Tchou J. PTGES3 is a putative prognostic marker in breast cancer. J Surg Res. 2022;271:154\u201362. https:\/\/doi.org\/10.1016\/j.jss.2021.08.033.","journal-title":"J Surg Res"},{"issue":"42","key":"431_CR22","doi-asserted-by":"publisher","first-page":"32775","DOI":"10.1074\/jbc.M003504200","volume":"275","author":"T Tanioka","year":"2000","unstructured":"Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem. 2000;275(42):32775\u201382. https:\/\/doi.org\/10.1074\/jbc.M003504200.","journal-title":"J Biol Chem"},{"issue":"3","key":"431_CR23","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1124\/pharmrev.123.000901","volume":"76","author":"A Santiso","year":"2024","unstructured":"Santiso A, Heinemann A, Kargl J. Prostaglandin E2 in the tumor microenvironment, a convoluted affair mediated by EP receptors 2 and 4. Pharmacol Rev. 2024;76(3):388\u2013413. https:\/\/doi.org\/10.1124\/pharmrev.123.000901.","journal-title":"Pharmacol Rev"},{"key":"431_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biology9120434","author":"F Finetti","year":"2020","unstructured":"Finetti F, Travelli C, Ercoli J, Colombo G, Buoso E, Trabalzini L. Prostaglandin E2 and cancer: insight into tumor progression and immunity. Biology. 2020. https:\/\/doi.org\/10.3390\/biology9120434.","journal-title":"Biology"},{"issue":"12","key":"431_CR25","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1128\/mcb.02314-06","volume":"27","author":"AK Lovgren","year":"2007","unstructured":"Lovgren AK, Kovarova M, Koller BH. cPGES\/p23 is required for glucocorticoid receptor function and embryonic growth but not prostaglandin E2 synthesis. Mol Cell Biol. 2007;27(12):4416\u201330. https:\/\/doi.org\/10.1128\/mcb.02314-06.","journal-title":"Mol Cell Biol"},{"key":"431_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13122","volume":"7","author":"Y He","year":"2016","unstructured":"He Y, Peng S, Wang J, Chen H, Cong X, Chen A, et al. Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. Nat Commun. 2016;7:13122. https:\/\/doi.org\/10.1038\/ncomms13122.","journal-title":"Nat Commun"},{"issue":"12","key":"431_CR27","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1038\/s41588-025-02388-8","volume":"57","author":"H Li","year":"2025","unstructured":"Li H, Melnyk JE, Fu BXH, Shrestha R, Zhang M, Sj\u00f6str\u00f6m M, et al. Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer. Nat Genet. 2025;57(12):3027\u201338. https:\/\/doi.org\/10.1038\/s41588-025-02388-8.","journal-title":"Nat Genet"},{"issue":"10","key":"431_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113246","volume":"42","author":"S Chen","year":"2023","unstructured":"Chen S, Wu Y, Gao Y, Wu C, Wang Y, Hou C, et al. Allosterically inhibited PFKL via prostaglandin E2 withholds glucose metabolism and ovarian cancer invasiveness. Cell Rep. 2023;42(10):113246. https:\/\/doi.org\/10.1016\/j.celrep.2023.113246.","journal-title":"Cell Rep"},{"issue":"1","key":"431_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22817-6","volume":"12","author":"DR Little","year":"2021","unstructured":"Little DR, Lynch AM, Yan Y, Akiyama H, Kimura S, Chen J. Differential chromatin binding of the lung lineage transcription factor NKX2-1 resolves opposing murine alveolar cell fates in vivo. Nat Commun. 2021;12(1):2509. https:\/\/doi.org\/10.1038\/s41467-021-22817-6.","journal-title":"Nat Commun"},{"issue":"2","key":"431_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.tig.2023.10.007","volume":"40","author":"A Barral","year":"2024","unstructured":"Barral A, Zaret KS. Pioneer factors: roles and their regulation in development. Trends Genet. 2024;40(2):134\u201348. https:\/\/doi.org\/10.1016\/j.tig.2023.10.007.","journal-title":"Trends Genet"},{"key":"431_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav1898","author":"MR Corces","year":"2018","unstructured":"Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W, et al. The chromatin accessibility landscape of primary human cancers. Science. 2018. https:\/\/doi.org\/10.1126\/science.aav1898.","journal-title":"Science"},{"issue":"7693","key":"431_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138. https:\/\/doi.org\/10.1038\/nature25501.","journal-title":"Nature"},{"issue":"2","key":"431_CR33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79(2):506\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.003.","journal-title":"J Hepatol"},{"issue":"3","key":"431_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151\u201372. https:\/\/doi.org\/10.1038\/s41571-021-00573-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"431_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cytogfr.2023.04.001","volume":"71-72","author":"M Turati","year":"2023","unstructured":"Turati M, Mousset A, Issa N, Turtoi A, Ronca R. TGF-\u03b2 mediated drug resistance in solid cancer. Cytokine Growth Factor Rev. 2023;71\u201372:54\u201365. https:\/\/doi.org\/10.1016\/j.cytogfr.2023.04.001.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"431_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","volume":"18","author":"R Derynck","year":"2021","unstructured":"Derynck R, Turley SJ, Akhurst RJ. TGF\u03b2 biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021;18(1):9\u201334. https:\/\/doi.org\/10.1038\/s41571-020-0403-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"431_CR37","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","volume":"40","author":"D L\u00f3pez-Terrada","year":"2009","unstructured":"L\u00f3pez-Terrada D, Cheung SW, Finegold MJ, Knowles BB. Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 2009;40(10):1512\u20135. https:\/\/doi.org\/10.1016\/j.humpath.2009.07.003.","journal-title":"Hum Pathol"},{"key":"431_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222313135","author":"VA Arzumanian","year":"2021","unstructured":"Arzumanian VA, Kiseleva OI, Poverennaya EV. The curious case of the HepG2 cell line: 40 years of expertise. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222313135.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"431_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008668","volume":"5","author":"M Daigneault","year":"2010","unstructured":"Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE. 2010;5(1):e8668. https:\/\/doi.org\/10.1371\/journal.pone.0008668.","journal-title":"PLoS ONE"},{"key":"431_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1546-9","volume":"15","author":"M Genin","year":"2015","unstructured":"Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577. https:\/\/doi.org\/10.1186\/s12885-015-1546-9.","journal-title":"BMC Cancer"},{"key":"431_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201601012","author":"JM de la Rios Rosa","year":"2017","unstructured":"de la Rios Rosa JM, Tirella A, Gennari A, Stratford IJ, Tirelli N. The CD44-mediated uptake of hyaluronic acid-based carriers in macrophages. Adv Healthc Mater. 2017. https:\/\/doi.org\/10.1002\/adhm.201601012.","journal-title":"Adv Healthc Mater"},{"issue":"12","key":"431_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"issue":"7","key":"431_CR43","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671\u20135. https:\/\/doi.org\/10.1038\/nmeth.2089.","journal-title":"Nat Methods"},{"key":"431_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155461","author":"A Memon","year":"2020","unstructured":"Memon A, Pyao Y, Jung Y, Lee JI, Lee WK. A modified protocol of diethylnitrosamine administration in mice to model hepatocellular carcinoma. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21155461.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"431_CR45","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, et al. 3D slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012;30(9):1323\u201341. https:\/\/doi.org\/10.1016\/j.mri.2012.05.001.","journal-title":"Magn Reson Imaging"},{"issue":"13","key":"431_CR46","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573-87.e29. https:\/\/doi.org\/10.1016\/j.cell.2021.04.048.","journal-title":"Cell"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00431-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00431-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00431-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:47:21Z","timestamp":1774432041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00431-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00431-6","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The human tissue collection and use were approved by the Ethics Committees of Shanghai Kewan Biology Co., Ltd. (Approval No. KW250613) and the First Affiliated Hospital of Anhui Medical University (Approval No. 2024052). All animal experiments were approved by the Institutional Animal Care and Use Committee of Hefei Cancer Hospital, Chinese Academy of Sciences (Approval No. DWLLPF-2024062001) and followed the Guide for the Care and Use of Laboratory Animals. Written informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declared no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}